These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 25213579)

  • 1. Response to cholinesterase inhibitors affects lifespan in Alzheimer's disease.
    Wattmo C; Londos E; Minthon L
    BMC Neurol; 2014 Sep; 14():173. PubMed ID: 25213579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early- versus late-onset Alzheimer's disease in clinical practice: cognitive and global outcomes over 3 years.
    Wattmo C; Wallin ÅK
    Alzheimers Res Ther; 2017 Aug; 9(1):70. PubMed ID: 28859660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohort.
    Wattmo C; Wallin AK; Minthon L
    BMC Neurol; 2012 Nov; 12():134. PubMed ID: 23126532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.
    Wattmo C; Minthon L; Wallin ÅK
    Alzheimers Res Ther; 2016 Feb; 8():7. PubMed ID: 26883213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression of mild Alzheimer's disease: knowledge and prediction models required for future treatment strategies.
    Wattmo C; Wallin AK; Minthon L
    Alzheimers Res Ther; 2013; 5(5):44. PubMed ID: 24099236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal Associations between Survival in Alzheimer's Disease and Cholinesterase Inhibitor Use, Progression, and Community-Based Services.
    Wattmo C; Londos E; Minthon L
    Dement Geriatr Cogn Disord; 2015; 40(5-6):297-310. PubMed ID: 26335053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-Term Response to Cholinesterase Inhibitors in Alzheimer's Disease Delays Time to Nursing Home Placement.
    Wattmo C; Londos E; Minthon L
    Curr Alzheimer Res; 2018; 15(10):905-916. PubMed ID: 29732972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease.
    Wattmo C; Blennow K; Hansson O
    BMC Neurol; 2020 Jan; 20(1):10. PubMed ID: 31918679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholinesterase inhibitors do not alter the length of stay in nursing homes among patients with Alzheimer's disease: a prospective, observational study of factors affecting survival time from admission to death.
    Wattmo C; Londos E; Minthon L
    BMC Neurol; 2016 Aug; 16(1):156. PubMed ID: 27581368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A naturalistic study of galantamine for Alzheimer's disease.
    Brodaty H; Woodward M; Boundy K; Barnes N; Allen G;
    CNS Drugs; 2006; 20(11):935-43. PubMed ID: 17044730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group.
    Raskind MA; Cyrus PA; Ruzicka BB; Gulanski BI
    J Clin Psychiatry; 1999 May; 60(5):318-25. PubMed ID: 10362441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors that affect life expectancy in Alzheimer's disease: a 15-year follow-up.
    Wattmo C; Londos E; Minthon L
    Dement Geriatr Cogn Disord; 2014; 38(5-6):286-99. PubMed ID: 24992891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.
    Santoro A; Siviero P; Minicuci N; Bellavista E; Mishto M; Olivieri F; Marchegiani F; Chiamenti AM; Benussi L; Ghidoni R; Nacmias B; Bagnoli S; Ginestroni A; Scarpino O; Feraco E; Gianni W; Cruciani G; Paganelli R; Di Iorio A; Scognamiglio M; Grimaldi LM; Gabelli C; Sorbi S; Binetti G; Crepaldi G; Franceschi C
    CNS Drugs; 2010 Feb; 24(2):163-76. PubMed ID: 20088621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.
    Morris JC; Cyrus PA; Orazem J; Mas J; Bieber F; Ruzicka BB; Gulanski B
    Neurology; 1998 May; 50(5):1222-30. PubMed ID: 9595967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.
    Porsteinsson AP; Grossberg GT; Mintzer J; Olin JT;
    Curr Alzheimer Res; 2008 Feb; 5(1):83-9. PubMed ID: 18288936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease?
    Wallin AK; Hansson O; Blennow K; Londos E; Minthon L
    Int J Geriatr Psychiatry; 2009 Jun; 24(6):638-47. PubMed ID: 19123199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of a loading-dose regimen versus a no-loading-dose regimen of metrifonate in the symptomatic treatment of Alzheimer's disease: a randomized, double-masked, placebo-controlled trial. Metrifonate Study Group.
    Jann MW; Cyrus PA; Eisner LS; Margolin DI; Griffin T; Gulanski B
    Clin Ther; 1999 Jan; 21(1):88-102. PubMed ID: 10090427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
    Mossello E; Tonon E; Caleri V; Tilli S; Cantini C; Cavallini MC; Bencini F; Mecacci R; Marini M; Bardelli F; Sarcone E; Razzi E; Biagini CA; Masotti G
    Arch Gerontol Geriatr Suppl; 2004; (9):297-307. PubMed ID: 15207427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatment.
    Wattmo C; Wallin ÅK; Londos E; Minthon L
    Alzheimer Dis Assoc Disord; 2011; 25(1):63-72. PubMed ID: 20847636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A longitudinal study of risk factors for community-based home help services in Alzheimer's disease: the influence of cholinesterase inhibitor therapy.
    Wattmo C; Paulsson E; Minthon L; Londos E
    Clin Interv Aging; 2013; 8():329-39. PubMed ID: 23682212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.